Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation

Br J Haematol. 2012 May;157(3):395-7. doi: 10.1111/j.1365-2141.2011.08991.x. Epub 2012 Jan 9.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carmustine / therapeutic use
  • Combined Modality Therapy
  • Cytarabine / therapeutic use
  • Etoposide / therapeutic use
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Lymphoma, B-Cell / radiotherapy*
  • Melphalan / therapeutic use
  • Radioimmunotherapy / methods*
  • Treatment Outcome
  • Yttrium Radioisotopes / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Yttrium Radioisotopes
  • Cytarabine
  • ibritumomab tiuxetan
  • Etoposide
  • Melphalan
  • Carmustine

Supplementary concepts

  • BEAM regimen